Placebo MDI match Budesonide clinical trials

A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)

This study is testing a new inhaler for adults with asthma that isn't well controlled. It compares a new triple-medicine inhaler to existing ones to see if it works better at preventing asthma attacks and improving breathing over 24-52 weeks.